GGrantIndex
← Leaderboards

Robert Alan Baiocchi

Ohio State University

$3,789,234
Attributed
$5,731,486
Total exposure
7
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $749.9K · FY200525
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$5,981,295 · 8

By mechanism

R01$2,290,108 · 1
P01$1,357,004 · 1
RC2$999,864 · 1
R38$422,504 · 1
R21$408,523 · 1
P30$249,809 · 1

Top collaborators

Most similar at Ohio State University

Same institution · by research overlap

Others in their field

Top investigators on “Programs

Research focus

ProgramsTumorPre-ClinicalClinical TrialsIn VivoImmuneLymphomaPathway InteractionsPharmaceutical PreparationsNovel StrategiesMalignant NeoplasmsCombined Modality TherapyEpigenetic ProcessTranslationsInnovationOverexpressionGene ExpressionPreventRegulationLeadAnimal ModelChromatinTherapeutic TargetTumor Suppressor Genes

Grant awards (18)

The Ohio State University Research in Residency Physician Scientist Initiative$422,504
R38 · FY2025 · AI
Targeting the Tumor Microenvironment in Patients with AIDS-Associated EBV+ Diffuse Large B Cell Lymphoma$249,809
P30 · FY2024 · CA
Project 3: Targeting PRMT5 in Mantle Cell Lymphoma$265,220
P01 · FY2022 · CA · contact PI
Targeted Therapies for Richters Transformation$463,172
R01 · FY2021 · CA
Project 3: Targeting PRMT5 in Mantle Cell Lymphoma$270,632
P01 · FY2021 · CA · contact PI
Targeted Therapies for Richters Transformation$463,172
R01 · FY2020 · CA
Project 3: Targeting PRMT5 in Mantle Cell Lymphoma$270,632
P01 · FY2020 · CA · contact PI
Targeted Therapies for Richters Transformation$449,278
R01 · FY2019 · CA
Project 3: Targeting PRMT5 in Mantle Cell Lymphoma$262,513
P01 · FY2019 · CA · contact PI
Targeted Therapies for Richters Transformation$461,935
R01 · FY2018 · CA
Project 3: Targeting PRMT5 in Mantle Cell Lymphoma$288,007
P01 · FY2018 · CA · contact PI
Targeted Therapies for Richters Transformation$452,551
R01 · FY2017 · CA
Development of novel compounds to inhibit PRMT5 enzyme in high grade astrocytomas$221,022
R21 · FY2011 · NS · contact PI
Development of Vaccine Strategies to prevent EBV+ Lymphoma in Patients with HIV$499,864
RC2 · FY2010 · CA · contact PI
Development of novel compounds to inhibit PRMT5 enzyme in high grade astrocytomas$187,501
R21 · FY2010 · NS · contact PI
Development of Vaccine Strategies to prevent EBV+ Lymphoma in Patients with HIV$500,000
RC2 · FY2009 · CA · contact PI
PTLD: cytokine production and gene polymorphisms$74,750
R03 · FY2005 · CA
BIOLOGIC MODIFIER THERAPIES IN AIDS MALIGNANCIES$178,733
U01 · FY2003 · CA